Singapore Offers Gateway to Asian Health Care Markets
The growth of markets within Asia is creating an enticing lure for medical device, pharmaceutical, and biomedical companies seeking to establish or enhance their presence in the region. Countries with large populations-and, in some cases, underserved medical needs for certain conditions-represent an opportunity to expand health care treatments. The government of Singapore is working hard to make sure foreign companies understand the island nation is very willing to offer that expertise and create an ideal location that could serve as a gateway to all of Asia.
You may also be interested in...
Although Japan has a reputation as a difficult market for new medical products to enter, the government and several public/private initiatives are making ground-breaking efforts to change that image. Several initiatives--some modeled after US Food & Drug Administration practices--will be launched in 2009. These changes, as well as others made in 2008, already are cutting into the drawn-out review times that manufacturers historically have had to face as a normal part of doing business in the country.
The latest accelerated approval withdrawals in the US are milestones for accountability in the program – most notably with the withdrawal of an antimicrobial with confirmatory studies more than a decade overdue.
Based on promising Phase II data, two companies in South Korea are moving ahead with late-stage development in the gout space, with JW Pharmaceutical getting approvals to begin a multinational Phase III trial for epaminurad, while LG Chem has recently submitted an application for a Phase III program with its contender tigulixostat.